Trials / Active Not Recruiting

Active Not RecruitingNCT06693128

Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer

Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Resectable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Prospective, Exploratory II Trial

Status: Active Not Recruiting
Phase: Phase 2
Study type: Interventional
Enrollment: 80 (estimated)

Sponsor: Ruijin Hospital · Academic / Other
Sex: All
Age: 18 Years
Healthy volunteers: Not accepted

Summary

This study is a multicenter, randomized, uncontrolled clinical trial to evaluate the efficacy and safety of camrelizumab combined with or without apatinib and SOX of neoadjuvant treatment for resectable locally advanced gastric or gastroesophageal junction adenocarcinoma.

Conditions

Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma

Interventions

Type	Name	Description
DRUG	Camrelizumab	Camrelizumab 200mg
DRUG	Apatinib	Apatinib 250mg
DRUG	S-1, Oxaliplatin	S-1, Oxaliplatin, q3w

Timeline

Start date: 2024-11-21
Primary completion: 2026-05-30
Completion: 2027-12-31
First posted: 2024-11-18
Last updated: 2026-01-28

Locations

3 sites across 1 country: China

Source: ClinicalTrials.gov record NCT06693128. Inclusion in this directory is not an endorsement.